Your Brain on THC: This Is What Happens When a Fat-Loving Molecule Hits the Brain

THC takes effect through one chemistry trick: it dissolves readily in fat. That property lets it cross the blood–brain barrier quickly, settle into fatty tissue, and linger long after the high fades. Older pharmacokinetic estimates suggest roughly 1% of a dose is present in the brain at peak effect — an estimate rather than a precise human measurement — but CB1 receptors are sensitive enough that this is plenty. Once there, THC does not act like a local signal. It behaves like a system-wide weather event.

One Puff and It's Already There

Delta-9-THC, chemical structure — AdeleDark, CC0, via Wikimedia Commons

Smoked THC moves from lung to blood almost immediately. In controlled studies, THC was detectable in plasma right after the first puff, plasma levels peaked within minutes, felt effects peaked around 15 to 30 minutes, and the typical smoked high tapered within 2 to 3 hours. Smoking is inefficient in a way that varies a lot from person to person: measured bioavailability ranged from 2% to 56%, depending on smoking dynamics and depth of inhalation.

Why an Edible Is Not Just Slower

Eating THC changes the trip because the drug takes a detour through the liver. The onset is delayed by roughly 30 to 90 minutes, the peak arrives at about 2 to 3 hours, and the effect can last 4 to 12 hours. First-pass liver metabolism also converts more THC into 11-hydroxy-THC, a metabolite that is itself psychoactive and roughly as potent as THC. That is one reason edibles can produce a different, sometimes more intense and prolonged experience than smoked cannabis, not merely a delayed one. Later, THC is oxidized into THC-COOH, which has no psychotropic effect and is the principal metabolite that standard urine drug tests target. Because THC is stored in fat and released slowly, THC-COOH can remain detectable long after the high is gone. In data reviewed by Franjo Grotenhermen, average urine detection lasted about 13 days in light users and about a month in heavy users, though individual windows vary widely with dose, frequency and test cutoff. A positive urine test shows exposure, not present impairment.

The Map Is the Message

THC's effects feel scattered because CB1 receptors are scattered. When cannabinoid receptors were mapped in the rat brain, binding was densest in the basal ganglia outflow nuclei involved in movement, dense in the hippocampus, dense in the cerebellum, high across the cortex, and present in the hypothalamus. That distribution reads almost like an index of cannabis effects: movement, memory, coordination, thought, perception, and appetite.

Just as important is where CB1 was relatively sparse: the lower brainstem centers that control breathing and cardiovascular function. Herkenham and colleagues wrote in 1990 that this pattern "may explain why high doses of delta 9-THC are not lethal." That receptor map is the classic explanation for why cannabis, unlike opioids, has no established record of fatal respiratory depression in humans. The honest caveat is that "not lethal" should not be inflated into "incapable of contributing to death under any circumstance." A 2014 forensic report described two sudden deaths attributed by the investigators to suspected cannabis-evoked cardiac arrhythmia after other causes were excluded: one man had an undetected heart problem, the other had a history of substance abuse. Lead author Benno Hartung later described the cases to the Associated Press as "very rare, isolated cases." The brainstem map is not the whole story, either: in 2025, researchers detected CB1 receptor mRNA in respiratory cells of the mouse pre-Bötzinger complex, a key breathing-control nucleus, and found that injected THC suppressed ventilation in awake mice. That is mouse evidence, not proof of danger in humans — but it means the 1990 explanation is best read as a strong hypothesis, not a settled guarantee.

A Volume Knob Turned Up in Every Room at Once

CB1 is built to be a brake. In normal signaling, endocannabinoids are released backward across a synapse and tell the presynaptic neuron to release less glutamate or less GABA for a short time. Anandamide and 2-AG are the local messengers that carry this signal. THC exploits the same receptor, but on very different terms. It is only a partial agonist at CB1 and CB2, yet it reaches the receptor everywhere at once and stays active for hours. A mechanism meant to fine-tune one conversation ends up lowering the volume across the whole brain.

Is the Reward System Really Being Flooded?

The dopamine story is subtler than the slogan. CB1 receptors are found mainly on the GABA and glutamate terminals that regulate dopamine neurons in the ventral tegmental area. Research has also identified functional CB1 receptors on a subset of the dopamine neurons themselves. In animal experiments, cannabinoid activation of CB1 receptors can reduce inhibitory GABA input to dopamine neurons, which can increase downstream dopamine signaling in the nucleus accumbens and striatum.

Human PET evidence for that effect is modest and inconsistent. In the key human study — a PET-imaging experiment only seven participants completed — inhaled THC produced only about 3% to 4% displacement of the dopamine tracer in the ventral striatum and dorsal putamen. Another study using oral dronabinol found no significant dopamine release. That is not the profile of a drug creating a stimulant-sized surge. With chronic heavy use, the picture can flip: marijuana abusers showed blunted brain responses to a stimulant challenge, even though baseline D2 receptor availability was not reduced. The researchers cautioned that these differences could reflect downstream dopamine-system adaptations rather than simply reduced dopamine release. The reward effect is real, indirect, and modest—not a cocaine-like flood.

Why Being High Feels Different From One Moment to the Next

Because CB1 density differs by region, the same wave of THC produces different effects as it crosses different circuits. In a double-blind human study of 22 healthy volunteers given intravenous THC, researchers saw euphoria, altered perception, anxiety, schizophrenia-like symptoms, impaired working memory and verbal fluency, and dose-dependent disruption of immediate and delayed word recall—but recognition memory and orientation remained intact. THC interferes most clearly with forming and retrieving fresh verbal material, not with recognizing information once it is presented again.

In the hippocampus, animal work gives a plausible cellular route for the memory gap. THC's amnesic effect in mice has been linked to CB1 receptors on GABAergic interneurons and downstream mTOR signaling; blocking that pathway abolished the memory deficit. In the hypothalamus, endocannabinoids help maintain food intake through CB1 signaling. Leptin interacts with hypothalamic endocannabinoid signaling, which helps explain how this system participates in appetite regulation and cannabis-associated appetite stimulation. And in a human study of 44 subjects given intravenous THC, the internal clock ran fast: people overestimated elapsed time and underproduced intervals at every dose, which is why minutes can feel stretched while high. Frequent users were blunted to that timing effect.

Tolerance Is Adaptation, Not Damage

Daily exposure changes the receptor landscape. In chronic daily smokers scanned with PET imaging, CB1 receptors were downregulated in a regionally selective way, especially in cortex, and the change correlated with years of smoking. Receptor density returned to normal after about four weeks of abstinence. Chronic users also show blunted dopamine reactivity. Tolerance, in other words, is neuroadaptation: repeated exposure is associated with reduced CB1 receptor availability, and that availability returns toward normal after abstinence.

Cells Under Stress Are Not the Same as Cells Being Killed

The claim that "THC kills brain cells" does not survive the evidence as a simple slogan. There is no established direct human evidence that typical recreational THC exposure destroys neurons. The cell literature is two-sided: cannabinoids can be neurotoxic in vitro at high concentrations, but they can also be neuroprotective in animal models of brain injury. The functional effects that are well demonstrated—memory disruption, altered timing, tolerance—are explained by receptor signaling changing while THC is present and by reversible receptor downregulation with heavy use. That is a very different claim from neuronal death.

The Teenage Brain Question Is Still Open

The adolescent question deserves its own caution label. During brain development, endocannabinoids help guide neuronal connections, so flooding the system during adolescence is biologically plausible as a concern. In the Dunedin cohort study, persistent cannabis use was associated with broad neuropsychological decline, especially in adolescent-onset users; the subgroup of 23 who began in adolescence and used most persistently showed an average decline of roughly eight IQ points — a subgroup figure, not an average for adolescent users generally — and some effects persisted after quitting among adolescent-onset users.

But the causal claim remains disputed. Ole Rogeberg showed that socioeconomic confounding could reproduce the Dunedin association, making the true effect possibly zero. The Dunedin team replied that socioeconomic status did not explain the decline in the actual data. Two longitudinal twin studies cut against the strongest version of the argument: cannabis-using twins showed no dose-response pattern and did not decline more than their abstinent co-twins. The responsible conclusion is not that the teen-brain risk is settled in either direction. It is that adolescence is a sensitive developmental period, the cohort signal is real enough to worry about, and the best causal tests have not confirmed the claim.

Read next

Anandamide: The Bliss Molecule Your Body Makes Itselfarticles · Nov 5, 2026The Endocannabinoid System: Why Your Body Has Cannabinoid Receptorsarticles · Nov 5, 2026

Sources

1. Berghuis, Paul, et al. "Hardwiring the Brain: Endocannabinoids Shape Neuronal Connectivity." *Science*, vol. 316, no. 5828, 2007, pp. 1212–1216. https://doi.org/10.1126/science.1137406
2. Bossong, Matthijs G., et al. "Δ9-Tetrahydrocannabinol Induces Dopamine Release in the Human Striatum." *Neuropsychopharmacology*, vol. 34, no. 3, 2009, pp. 759–766. https://doi.org/10.1038/npp.2008.138
3. D'Souza, Deepak Cyril, et al. "The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis." *Neuropsychopharmacology*, vol. 29, no. 8, 2004, pp. 1558–1572. https://doi.org/10.1038/sj.npp.1300496
4. Di Marzo, Vincenzo, et al. "Leptin-Regulated Endocannabinoids Are Involved in Maintaining Food Intake." *Nature*, vol. 410, no. 6830, 2001, pp. 822–825. https://doi.org/10.1038/35071088
5. Grotenhermen, Franjo. "Pharmacokinetics and Pharmacodynamics of Cannabinoids." *Clinical Pharmacokinetics*, vol. 42, no. 4, 2003, pp. 327–360. https://doi.org/10.2165/00003088-200342040-00003
6. Hartung, Benno, et al. "Sudden Unexpected Death under Acute Influence of Cannabis." *Forensic Science International*, vol. 237, 2014, pp. 95–98. https://doi.org/10.1016/j.forsciint.2014.02.001
7. Herkenham, Miles, et al. "Cannabinoid Receptor Localization in Brain." *Proceedings of the National Academy of Sciences*, vol. 87, no. 5, 1990, pp. 1932–1936. https://doi.org/10.1073/pnas.87.5.1932
8. Herkenham, Miles, et al. "Characterization and Localization of Cannabinoid Receptors in Rat Brain: A Quantitative in Vitro Autoradiographic Study." *Journal of Neuroscience*, vol. 11, no. 2, 1991, pp. 563–583.
9. Hirvonen, Jussi, et al. "Reversible and Regionally Selective Downregulation of Brain Cannabinoid CB1 Receptors in Chronic Daily Cannabis Smokers." *Molecular Psychiatry*, vol. 17, no. 6, 2012, pp. 642–649. https://doi.org/10.1038/mp.2011.82
10. Jackson, Nicholas J., et al. "Impact of Adolescent Marijuana Use on Intelligence: Results from Two Longitudinal Twin Studies." *Proceedings of the National Academy of Sciences*, vol. 113, no. 5, 2016, pp. E500–E508. https://doi.org/10.1073/pnas.1516648113
11. Kano, Masanobu, et al. "Endocannabinoid-Mediated Control of Synaptic Transmission." *Physiological Reviews*, vol. 89, no. 1, 2009, pp. 309–380. https://doi.org/10.1152/physrev.00019.2008
12. Meier, Madeline H., et al. "Persistent Cannabis Users Show Neuropsychological Decline from Childhood to Midlife." *Proceedings of the National Academy of Sciences*, vol. 109, no. 40, 2012, pp. E2657–E2664. https://doi.org/10.1073/pnas.1206820109
13. Melis, Miriam, et al. "Endocannabinoids Mediate Presynaptic Inhibition of Glutamatergic Transmission in Rat Ventral Tegmental Area Dopamine Neurons through Activation of CB1 Receptors." *Journal of Neuroscience*, vol. 24, no. 1, 2004, pp. 53–62. https://doi.org/10.1523/JNEUROSCI.4503-03.2004
14. Melis, Miriam, et al. "Prefrontal Cortex Stimulation Induces 2-Arachidonoylglycerol-Mediated Suppression of Excitation in Dopamine Neurons." *Journal of Neuroscience*, vol. 24, no. 47, 2004, pp. 10707–10715. https://doi.org/10.1523/JNEUROSCI.3502-04.2004
15. Moffitt, Terrie E., et al. "Reply to Rogeberg and Daly: No Evidence That Socioeconomic Status or Personality Differences Confound the Association between Cannabis Use and IQ Decline." *Proceedings of the National Academy of Sciences*, vol. 110, no. 11, 2013, pp. E980–E982. https://doi.org/10.1073/pnas.1300618110
16. Pertwee, Roger G. "The Diverse CB1 and CB2 Receptor Pharmacology of Three Plant Cannabinoids: Δ9-Tetrahydrocannabinol, Cannabidiol and Δ9-Tetrahydrocannabivarin." *British Journal of Pharmacology*, vol. 153, no. 2, 2008, pp. 199–215. https://doi.org/10.1038/sj.bjp.0707442
17. Puighermanal, Emma, et al. "Cannabinoid Modulation of Hippocampal Long-Term Memory Is Mediated by mTOR Signaling." *Nature Neuroscience*, vol. 12, no. 9, 2009, pp. 1152–1158. https://doi.org/10.1038/nn.2369
18. Riegel, Alicia C., and Carl R. Lupica. "Independent Presynaptic and Postsynaptic Mechanisms Regulate Endocannabinoid Signaling at Multiple Synapses in the Ventral Tegmental Area." *Journal of Neuroscience*, vol. 24, no. 49, 2004, pp. 11070–11078.
19. Rogeberg, Ole. "Correlations between Cannabis Use and IQ Change in the Dunedin Cohort Are Consistent with Confounding from Socioeconomic Status." *Proceedings of the National Academy of Sciences*, vol. 110, no. 11, 2013, pp. 4251–4254. https://doi.org/10.1073/pnas.1215678110
20. Sarne, Yosefa, et al. "The Dual Neuroprotective–Neurotoxic Profile of Cannabinoid Drugs." *British Journal of Pharmacology*, vol. 163, no. 7, 2011, pp. 1391–1401. https://doi.org/10.1111/j.1476-5381.2011.01280.x
21. Sewell, R. Andrew, et al. "Acute Effects of THC on Time Perception in Frequent and Infrequent Cannabis Users." *Psychopharmacology*, vol. 226, no. 2, 2013, pp. 401–413. https://doi.org/10.1007/s00213-012-2915-6
22. Stokes, Paul R. A., et al. "Can Recreational Doses of THC Produce Significant Dopamine Release in the Human Striatum?" *NeuroImage*, vol. 48, no. 2, 2009, pp. 402–407.
23. Volkow, Nora D., et al. "Decreased Dopamine Brain Reactivity in Marijuana Abusers Is Associated with Negative Emotionality and Addiction Severity." *Proceedings of the National Academy of Sciences*, vol. 111, no. 30, 2014, pp. E3149–E3156. https://doi.org/10.1073/pnas.1411228111
24. Wilson, Rachel I., and Roger A. Nicoll. "Endogenous Cannabinoids Mediate Retrograde Signalling at Hippocampal Synapses." *Nature*, vol. 410, no. 6828, 2001, pp. 588–592. https://doi.org/10.1038/35069076
25. Huestis, Marilyn A. "Human Cannabinoid Pharmacokinetics." *Chemistry & Biodiversity*, vol. 4, no. 8, 2007, pp. 1770–1804. https://doi.org/10.1002/cbdv.200790152
26. Watkins, Joshua, et al. "CB1 Cannabinoid Receptor Agonists Induce Acute Respiratory Depression in Awake Mice." *Pharmacological Research*, vol. 214, 2025, article 107682. https://doi.org/10.1016/j.phrs.2025.107682
27. Han, Xiao, et al. "Cannabinoid CB1 Receptors Are Expressed in a Subset of Dopamine Neurons and Underlie Cannabinoid-Induced Aversion, Hypoactivity, and Anxiolytic Effects in Mice." *Journal of Neuroscience*, vol. 43, no. 3, 2023, pp. 373–385. https://doi.org/10.1523/JNEUROSCI.1493-22.2022
28. Associated Press. News report on Hartung et al. (2014), quoting lead author Benno Hartung describing the two cases as "very rare, isolated cases." 2014.